Action to Take: Sell Catalent at a Profit
On February 5, drug manufacturer Catalent (NYSE: CTLT) announced it would sell itself to Novo Nordisk (NYSE: NVO) for $63.50 per share in cash – about $11.5 billion in total. This share price is a 17% premium to the prior closing price of $54.51 on Friday, February 2, and an increase of 40% since we
Read More …
